Bloomberg / Getty Images
On Wednesday, Bristol-Myers Squibb unveiled a deal with Anthropic that will give access to the AI company's Claude model to a workforce of more than 30,000, targeting faster progress in finding, developing, and delivering new medicines.
As part of the arrangement, Bristol-Myers Squibb is deploying Claude Code — Anthropic's tool aimed at developers — to accelerate how quickly its engineering and AI teams can work. The company is also exploring how Claude AI agents might be applied across research and drug development, manufacturing, and commercial and medical affairs.
Greg Meyers, Bristol-Myers Squibb's chief digital and technology officer, said the company's goal is to connect its various data sources through a common AI layer. "A lot of it is us avoiding having to build basic infrastructure tooling, so that we can really focus on the use cases that are going to bring more medicines to more patients faster," Meyers told The Wall Street Journal.
One application already in use involves Claude writing regulatory reports based on the company's clinical trial data. That requires the AI to understand Bristol-Myers Squibb's regulatory strategy and the style of its existing regulatory documents.
